How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/irbesartan-atorvastatin-fixed-dose-combination.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Irbesartan/atorvastatin fixed dose combination — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Irbesartan/atorvastatin fixed dose combination (Irbesartan/atorvastatin fixed dose combination) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: ARB/statin combination. Area: Cardiovascular.

marketed ARB/statin combination Angiotensin II type 1 receptor (AT1R) and HMG-CoA reductase Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Irbesartan/atorvastatin fixed dose combination (Irbesartan/atorvastatin fixed dose combination) — Sanofi. This fixed-dose combination lowers blood pressure by blocking angiotensin II receptors while simultaneously reducing cholesterol by inhibiting HMG-CoA reductase.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Irbesartan/atorvastatin fixed dose combination TARGET	Irbesartan/atorvastatin fixed dose combination	Sanofi	marketed	ARB/statin combination	Angiotensin II type 1 receptor (AT1R) and HMG-CoA reductase
valsartan, fluvastatin	valsartan, fluvastatin	Novartis	marketed	ARB/statin combination	Angiotensin II type 1 receptor (AT1R) and HMG-CoA reductase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (ARB/statin combination class)

Novartis · 1 drug in this class
Sanofi · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Irbesartan/atorvastatin fixed dose combination — Competitive Intelligence Brief. https://druglandscape.com/ci/irbesartan-atorvastatin-fixed-dose-combination. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab